IRIS Institutional Research Information System - AIR Archivio Istituzionale della Ricerca

The clinical advantage of high-dose therapy (HDT) over standard treatment for multiple myeloma (MM) patients has been recently assessed. Which patient subgroups benefit most from this approach is unclear.

An analysis of which subgroups of multiple myeloma patients, divided according to b(2)-microglobulin and plasma cell labeling index, benefit from high dose vs conventional chemotherapy / M. Boccadoro, C. Tarella, A. Palumbo, C. Argentino, S. Triolo, A. Dominietto, V. Callea, V. M. Lauta, S. Molica, P. Musto, F. Marmont, A. M. Gianni, A. Pileri. - In: HAEMATOLOGICA. - ISSN 0390-6078. - 84:10(1999 Oct), pp. 905-10-910.

An analysis of which subgroups of multiple myeloma patients, divided according to b(2)-microglobulin and plasma cell labeling index, benefit from high dose vs conventional chemotherapy

C. Tarella;A. M. Gianni
Penultimo
;
1999

Abstract

The clinical advantage of high-dose therapy (HDT) over standard treatment for multiple myeloma (MM) patients has been recently assessed. Which patient subgroups benefit most from this approach is unclear.
Severity of Illness Index; Disease-Free Survival; Cell Count; Antineoplastic Agents; Dose-Response Relationship, Drug; Humans; Longitudinal Studies; Multiple Myeloma; Plasma Cells; Survival Rate; Treatment Outcome; Antineoplastic Combined Chemotherapy Protocols; Follow-Up Studies; Middle Aged; beta 2-Microglobulin
Settore MED/06 - Oncologia Medica
ott-1999
HAEMATOLOGICA
Article (author)
01 - Articolo su periodico
File in questo prodotto:
Non ci sono file associati a questo prodotto.
Pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2434/184555
Citazioni
  • ???jsp.display-item.citation.pmc??? 0
  • Scopus 12
  • ???jsp.display-item.citation.isi??? 13
social impact